

European CNS specialist Neuraxpharm starts operations in Poland

Neuraxpharm Polska to drive growth in significant market

Appoints Wojciech Góra as General Manager

April 03, 2019

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces expansion in Eastern Europe with the launch of Neuraxpharm Polska and the appointment of Dr. Wojciech Góra as General Manager to spearhead the business. Dr. Góra brings over 20 years of experience in building and managing European pharmaceuticals operations and will be responsible for Neuraxpharm Polska located in Warsaw.

To date, Neuraxpharm has provided its high-quality medicines to CNS specialists and patients in Poland through its German subsidiary under the NeuroPharma brand. A key pillar of Neuraxpharm's growth strategy is to establish its own operations in high growth markets in Europe. Neuraxpharm aims to build its position as a CNS specialist in Poland offering nutraceuticals, standard generics and added value medicines and plans to launch five new CNS products in 2019. Neuraxpharm is investing in its pipeline by developing differentiated and high-tech barrier products in CNS that will be launched in Poland as well as in other Neuraxpharm countries.

Commenting on the news, Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: *"We are very pleased to launch Neuraxpharm Poland and to welcome Wojciech to our team. Neuraxpharm today has a direct presence in nine European countries and establishing Neuraxpharm Polska reinforces our ambition to be a leading CNS player in the CEE region and help bring differentiated products to local patients and healthcare professionals."*

Dr. Wojciech Góra, newly appointed General Manager, Neuraxpharm Polska added: *"I am delighted to join Neuraxpharm at this exciting stage in the company's growth. Poland is the sixth biggest CNS European market with double digit growth. I look forward to building and establishing Neuraxpharm as a recognised and trusted partner as we look towards launching new CNS products in the region."*

Dr. Góra has over 20 years of experience in the pharmaceutical industry. He joins Neuraxpharm from Meda Pharmaceuticals where he held numerous senior roles including launching and building Meda in Poland as Country Manager and Vice-President of the Management Board. In addition, he was also Regional Manager, Poland, Ukraine & CIS of Meda AB from 2015-17. At Meda, he grew net sales ten-fold over 10 years. Dr. Góra was also leading Rottapharm Madaus in Poland between 2014-16 and was responsible for its full integration post the Meda acquisition. He started his career at Astellas Pharma (previously Yamanouchi Pharma) where he held several positions in marketing and sales. Dr. Góra has a medical degree from the Medical Academy in Krakow.



For further information please contact:

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Tel: +44 203 950 9144

Email: neuraxpharm@optimumcomms.com

About Neuraxpharm – the European CNS specialist

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, Italy, France, United Kingdom, Poland, Czech Republic, Slovakia and Hungary. Backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market built over 30 years.

Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals, as well as consumer healthcare products e.g. nutraceuticals and probiotics, offering a wide range of effective, differentiated and affordable CNS treatments.

Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical forms and active pharmaceutical ingredients from its own manufacturing sites in Spain.